Is IGC Pharma Inc halal to invest in?

According to Musaffa's Shariah screening methodology, IGC Pharma Inc (IGC) is currently classified as HALAL as of March 2026. The classification is based on an evaluation of the company's business activities and financial ratios to determine whether it meets Islamic investment guidelines.

Is IGC Pharma Inc a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes IGC Pharma Inc using these criteria to determine its compliance status.

Can Muslims buy shares of IGC Pharma Inc?

Muslim investors may consider investing in IGC Pharma Inc if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is IGC Pharma Inc classified as HALAL?

Musaffa determines the Shariah status of IGC Pharma Inc by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for IGC Pharma Inc updated?

The Shariah compliance status of IGC Pharma Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like IGC Pharma Inc become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of IGC Pharma Inc?

You can check the latest Shariah compliance status of IGC Pharma Inc on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

IGC Shariah Compliance

Screening Methodology: AAOIFI

HALAL

Last Updated: March 31, 2026

Report Source: 2026 3rd Quarter Report

IGC Pharma Inc. Stock Analysis IGC

United States Health Care Nano Cap Report: Q3, 2026

IGC Pharma, Inc. is a clinical-stage pharmaceutical company that is focused on Alzheimer's disease, developing innovative solutions to address this devastating illness. The firm's lead asset, IGC-AD1, is a cannabinoid-based therapy is in a Phase 2 trial (CALMA) for agitation in Alzheimer's dementia. The Company’s pipeline includes TGR-63, targeting amyloid plaques, and early-stage programs focused on neurodegeneration, tau proteins, and metabolic dysfunctions. The firm integrates AI to accelerate drug discovery, optimize clinical trials, and enhance patient targeting. The company is also developing a Multimodal Interpretable Transformer for Alzheimer’s Disease (MINT-AD). MINT-AD leverages diverse data sources, including brain scans, genetics, lifestyle, and cognitive metrics, to produce clinically interpretable risk profiles and forecast decline trajectories.

Key Statistics of IGC Pharma Inc (IGC)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

$0.29$0.30

Today's Open

$0.29

Volume

244.59K

P/E Ratio (TTM)

52 Week Range

$0.24$0.50

Market Cap

31.83M

Avg. Volume

2.29M

Dividend Yield

Financial Metrics & Statements of IGC Pharma Inc (IGC)

FAQ's for IGC Pharma Inc (IGC)

According to Musaffa’s Shariah screening methodology, IGC Pharma Inc (IGC) is currently classified as HALAL as of March 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.